Compared with Q4 2025, management shifted from “well on track to initiate dosing” (Q4) to confirming enrollment and dosing are underway (Q1): Payne said in Q1, “Our 12-week Phase II study began ...

Thank you, Neda. The first quarter of 2026 was a period of solid execution for Arcturus as we continue to advance our rare disease pipeline and strengthen our leadership team. Because Class I CF is a ...

The consensus estimate for Q1 2026 revenue is $7.23 million, and the earnings are expected to come in at -$1.00 per share. The full year 2026's revenue is expected to be $38.51 million and the ...

Arcturus Therapeutics (ARCT) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.14. This compares to a loss of $0.52 per share a year ago. These ...